Current:Home > NewsPerson accused of accosting Rep. Nancy Mace at Capitol pleads not guilty to assault charge -Mastery Money Tools
Person accused of accosting Rep. Nancy Mace at Capitol pleads not guilty to assault charge
View
Date:2025-04-13 05:42:50
WASHINGTON (AP) — A person accused of accosting U.S. Rep. Nancy Mace in a Capitol Office building pleaded not guilty on Wednesday to a misdemeanor assault charge.
Witnesses told police that James McIntyre, 33, of Chicago, shook Mace’s hand in an “exaggerated, aggressive” manner after approaching the South Carolina Republican in the Rayburn House Office Building on Tuesday evening, according to a police affidavit.
Mace, who is identified only by her initials in a court filing, posted a string of social media messages about the incident. She said she was “physically accosted” at the Capitol, and she thanked President-elect Donald Trump for calling her Wednesday morning to check on her condition.
“I’m going to be fine just as soon as the pain and soreness subside,” Mace wrote.
Mace declined to be treated by a paramedic after her encounter with McIntyre, who was arrested Tuesday by the Capitol Police, the affidavit says.
Mace told police that McIntyre said, “Trans youth serve advocacy,” while shaking her hand. Last month, Mace proposed a resolutionthat would prohibit any lawmakers and House employees from “using single-sex facilities other than those corresponding to their biological sex.” Mace said the bill is aimed specifically at Delaware Democrat Sarah McBride — the first transgender personto be elected to Congress.
A magistrate judge ordered McIntyre’s release after an arraignment in Superior Court of the District of Columbia.
Efforts to reach an attorney for McIntyre weren’t immediately successful.
Disclaimer: The copyright of this article belongs to the original author. Reposting this article is solely for the purpose of information dissemination and does not constitute any investment advice. If there is any infringement, please contact us immediately. We will make corrections or deletions as necessary. Thank you.
veryGood! (44836)
Related
- $73.5M beach replenishment project starts in January at Jersey Shore
- Line 3 Drew Thousands of Protesters to Minnesota This Summer. Last Week, Enbridge Declared the Pipeline Almost Finished
- Adele Pauses Concert to Survey Audience on Titanic Sub After Tragedy at Sea
- California will cut ties with Walgreens over the company's plan to drop abortion pills
- Elon Musk's skyrocketing net worth: He's the first person with over $400 billion
- Charting a Course to Shrink the Heat Gap Between New York City Neighborhoods
- 25,000+ Amazon Shoppers Say This 15-Piece Knife Set Is “The Best”— Save 63% On It Ahead of Prime Day
- Amber Heard Makes Red Carpet Return One Year After Johnny Depp Trial
- Military service academies see drop in reported sexual assaults after alarming surge
- Man, woman charged with kidnapping, holding woman captive for weeks in Texas
Ranking
- Sam Taylor
- Charting a Course to Shrink the Heat Gap Between New York City Neighborhoods
- Medical debt affects millions, and advocates push IRS, consumer agency for relief
- The value of good teeth
- The company planning a successor to Concorde makes its first supersonic test
- SEC Proposes Landmark Rule Requiring Companies to Tell Investors of Risks Posed by Climate Change
- Exploring Seinfeld through the lens of economics
- Black married couples face heavier tax penalties than white couples, a report says
Recommendation
Krispy Kreme offers a free dozen Grinch green doughnuts: When to get the deal
From Denial to Ambiguity: A New Study Charts the Trajectory of ExxonMobil’s Climate Messaging
Businessman Who Almost Went on OceanGate Titanic Dive Reveals Alleged Texts With CEO on Safety Concerns
Theme Park Packing Guide: 24 Essential Items You’ll Want to Bring to the Parks This Summer
Highlights from Trump’s interview with Time magazine
Katy Perry Gives Update on Her Sobriety Pact With Orlando Bloom
DOJ sues to block JetBlue-Spirit merger, saying it will curb competition
FDA has new leverage over companies looking for a quicker drug approval